{"id":901099,"date":"2025-10-28T09:45:35","date_gmt":"2025-10-28T13:45:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/"},"modified":"2025-10-28T09:45:35","modified_gmt":"2025-10-28T13:45:35","slug":"strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/","title":{"rendered":"STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">HORSHAM, Pa., Oct.  28, 2025  (GLOBE NEWSWIRE) &#8212; STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies for the treatment of skin conditions such as acne, psoriasis, and vitiligo, today announced that its TheraClearX\u00ae acne treatment system has received regulatory clearance from the Mexican health authority, COFEPRIS (Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios), under Device Registration No. 3187E2024SSA, valid through November 2029.<\/p>\n<p align=\"justify\">This certification represents a major milestone in STRATA\u2019s international expansion strategy, officially authorizing the importation, commercialization, and clinical use of TheraClearX\u00ae across Mexico\u2019s medical and aesthetic markets.<\/p>\n<p>\n        <strong>Regulatory Clearance and Initial Launch<\/strong>\n      <\/p>\n<p align=\"justify\">The COFEPRIS medical device registration process, which typically spans 6 to 12 months, involves a detailed review of device safety, efficacy, and quality documentation aligned with international standards. The granting of Registration No. 3187E2024SSA confirms that STRATA technologies meet Mexico\u2019s rigorous regulatory requirements for dermatologic medical devices.<\/p>\n<p align=\"justify\">Following certification, STRATA has initiated its commercial rollout in partnership with MINO Labs, a leading Mexican pharmaceutical and medical device commercialization firm. The first TheraClearX\u00ae system has been placed with Dr. Melissa Lomel\u00ed Canedo in Mexico City.<\/p>\n<p align=\"justify\">Dr. Canedo will be the first in Mexico to offer TheraClearX\u00ae\u2019s photopneumatic technology \u2014 a non-drug, device-based therapy that targets acne at its source through deep cleansing and light-based treatment, producing visible results with minimal downtime. She is a graduate of Hospital General de M\u00e9xico \u201cDr.\u00a0Eduardo Liceaga\u201d (Ministry of Health). She completed fellowships in Dermatologic and Mohs Surgery at Hospital Clinic Barcelona, in Trichology in S\u00e3o Paulo, Brazil, and in Dermatologic Oncology in Salzburg, Austria, Medical Institute (January 2024). She holds a diploma in Dermato-oncology, CILAD and completed a medical rotation at Polyclinic Hospital Di SANT ORSOLA, Bologna, Italy.<\/p>\n<p>\n        <strong>Market Potential in Mexico<\/strong>\n      <\/p>\n<p align=\"justify\">The acne treatment market in Mexico represents a substantial and fast-growing opportunity:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt;text-align:justify\">The professional acne medication segment is projected to nearly double by 2030 (CAGR~10.2%)<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\">An average acne treatment session costs around MXN 3,200 (\u2248 USD 174), positioning TheraClearX\u00ae competitively within the premium in-office care segment<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\">Mexico has approximately 3,000 licensed dermatologists, all trained to treat inflammatory skin conditions; however, most lack access to advanced phototherapeutic and device-based solutions \u2014 highlighting the strong market potential for TheraClearX\u00ae and XTRAC\u00ae\n<\/li>\n<\/ul>\n<p align=\"justify\">\u201cThe clearance of TheraClearX\u00ae by COFEPRIS expands STRATA\u2019s reach into a fast-growing, innovation-driven dermatology market,\u201d said Shmuel Gov, STRATA Skin Sciences Chief Operating Officer. \u201cWith Mino Labs as a strong local partner, and its Mino Derm &amp; Aesthetics Dermatology Division, we are positioned to rapidly scale physician adoption and make proven, device-based dermatologic care more accessible across Mexico by taking advantage of the unique placement worry free business model we can offer.\u201d<\/p>\n<p>\n        <strong>Strategic Partnership with MINO Labs<\/strong>\n      <\/p>\n<p align=\"justify\">MINO Labs, and its Aesthetics Dermatology Division headquartered in Mexico City, has built a nationwide commercialization network encompassing over 3,000 dermatologists and aesthetic practitioners. Its integrated model \u2014 combining regulatory affairs, logistics, marketing, and clinical training \u2014 provides STRATA with immediate access to a robust professional base for rapid deployment.<\/p>\n<p align=\"justify\">\u201cWe are proud to partner with STRATA in introducing advanced acne and phototherapy solutions to the Mexican market,\u201d said Manuel Cosme, MINO Labs Owner and President. \u201cMexico has approximately 3,000 dermatologists, all trained to treat inflammatory skin conditions, yet most clinics lack access to the right equipment to do so effectively. TheraClearX\u00ae bridges that gap, empowering dermatologists with the latest U.S. technology. We believe this partnership will significantly elevate the standard of dermatologic care in Mexico and drive meaningful growth over the coming years.\u201d<\/p>\n<p>\n        <strong>Usage-Based Model Mirroring U.S. Success<\/strong>\n      <\/p>\n<p align=\"justify\">As in the United States, TheraClearX\u00ae will be offered in Mexico under STRATA\u2019s usage-based partnership model, allowing physicians to acquire and operate the device with no upfront capital investment, paying only per treatment performed. This structure minimizes financial barriers for clinics, aligns incentives with patient outcomes, and supports a recurring revenue model for STRATA and its partners.<\/p>\n<p>\n        <strong>Forward Outlook<\/strong><br \/>\n        <br \/>With COFEPRIS certification secured and initial placements underway, STRATA plans to:<br \/>1. Expand device deployment to major metropolitan areas including Guadalajara, Monterey, Puebla, and Tijuana.<br \/>2. Launch clinical education programs with MINO Labs for dermatologists and clinic staff.<br \/>3. Gather real-world clinical data to support broader adoption.<br \/>4. Evaluate additional device registrations and indications for Latin America in 2026.<br \/>5. Participate on the TERACILAD conference in Mexico City on November 20<sup>th<\/sup> &#8211; 22<sup>nd<\/sup> 2025<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0STRATA Skin Sciences, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">STRATA Skin Sciences\u00a0is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC<sup>\u00ae<\/sup>\u00a0excimer laser, VTRAC<sup>\u00ae<\/sup>\u00a0lamp systems, and the TheraClear<sup>\u00ae<\/sup>X Acne Therapy System.<\/p>\n<p align=\"justify\">STRATA is proud to offer these exciting technologies in the\u00a0U.S.\u00a0through its unique Partnership Program. STRATA\u2019s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.<\/p>\n<p>\n        <strong>About MINO Labs<\/strong>\n      <\/p>\n<p>MINO Labs S.A. de C.V. is a Mexico-based pharmaceutical and medical technology company specializing in the representation and commercialization of innovative therapeutic and wellness products. With established relationships across 3,000 dermatologists in Mexico, MINO Labs provides a comprehensive commercialization platform encompassing research, regulatory affairs, marketing, and nationwide distribution. For more information, visit www.minolabs.com.<\/p>\n<p>\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p>This press release includes &#8220;forward-looking statements&#8221; within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company\u2019s plans, objectives, expectations and intentions and may contain words such as \u201cwill,\u201d \u201cmay,\u201d \u201cseeks,\u201d and \u201cexpects,\u201d that suggest future events or trends. These statements, the Company\u2019s ability to launch and sell products recently acquired or to be developed in the future, the Company\u2019s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company\u2019s ability to build a leading franchise in dermatology and aesthetics, are based on the Company\u2019s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company\u2019s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, tariffs, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company\u2019s\u00a0SEC\u00a0reports on Forms 10-Q and 10-K. Given\u00a0such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC\u00a0disclosures available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SGlBHW_WHHEPFadLN_bmMsvcotmYPZc-fjnV53MxhMyQjPSW_7FdksDRLBrJFeYkv1EgbJTaGgRGl8wkk456MURxBvLjImYIsC9HuTx_2480g1XDpstpedqbwm3UFv-lEOwHAQaZ50TSq5LlpN5Oy4VPZF30aqtBHnT_nY3Ea-01e-pkmQLyU1IEwVzRK6OjMjwYLBR74KTSAavq2ptbRvisgR3YIGH1j3CmwTgTfcI=\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SGlBHW_WHHEPFadLN_bmMmBlAxl-7sVafWEjNRKFZkpxjiW8mPnEUaO0MO27aXv2F4AuZ-p50SzqjTLkXOJp6z8APbv8MoJREmWvILS5nbFhcTNRMy4fgSvt_d0wSzYsGIKDDVUlsEakMRZJ95EGCj-Kahuo7kqDwXCKzV1Q-nTA4ibhLsDp46TUJ0BihlxRzXL5JUf8ULKOC5nAAVe2u62t8-LxMqUzlMyC99OkmZm0bD4LrpmbVYkTmYZHkTwX12BfxDb6En3JJ1OOwObcuTIFqHFpTUEmxc1wWa_jcB84pm8xbgnNp4y6FF6N77PB\" rel=\"nofollow\" target=\"_blank\">www.strataskinsciences.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>CORE IR<br \/>516-222-2560<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IOiriwMfQUXCIg5Y7aEHRSptqrxUkfIt_2cOwzGC9pGEgInZyw_GowGzinC3MwAf_ENcfmld58hmzffdW10Hwo_--AQmrYcoelXfsGGNoi_Jn8Lb9C-u-BiDJEBd1INi1Pklpe4r9oxP7RU_8K4en7Sd0IUW3eg974h9Y5foNSMDErYDlDWhkiU5GcjXhD0mhrhNhTf3Av1mcKkzI1aJkIBey5XL0BMenkw1xAmFf36dcXuc3UzByoBSz2qTN8Y229QJGbbe4J3TQegQxCEiBw==\" rel=\"nofollow\" target=\"_blank\">IR@strataskin.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjU5NCM3MjI2MjYxIzIwMTA1MTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTZmYzE4YzAtNDYwMC00ZjE3LWJhM2YtNWI1ZWE4MWQ5ZTE1LTEwMjIwODctMjAyNS0xMC0yOC1lbg==\/tiny\/STRATA-Skin-Sciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HORSHAM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) &#8212; STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies for the treatment of skin conditions such as acne, psoriasis, and vitiligo, today announced that its TheraClearX\u00ae acne treatment system has received regulatory clearance from the Mexican health authority, COFEPRIS (Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios), under Device Registration No. 3187E2024SSA, valid through November 2029. This certification represents a major milestone in STRATA\u2019s international expansion strategy, officially authorizing the importation, commercialization, and clinical use of TheraClearX\u00ae across Mexico\u2019s medical and aesthetic markets. Regulatory Clearance and Initial Launch The COFEPRIS medical device registration process, which typically spans 6 to 12 months, involves a detailed review of device safety, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-901099","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HORSHAM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) &#8212; STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies for the treatment of skin conditions such as acne, psoriasis, and vitiligo, today announced that its TheraClearX\u00ae acne treatment system has received regulatory clearance from the Mexican health authority, COFEPRIS (Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios), under Device Registration No. 3187E2024SSA, valid through November 2029. This certification represents a major milestone in STRATA\u2019s international expansion strategy, officially authorizing the importation, commercialization, and clinical use of TheraClearX\u00ae across Mexico\u2019s medical and aesthetic markets. Regulatory Clearance and Initial Launch The COFEPRIS medical device registration process, which typically spans 6 to 12 months, involves a detailed review of device safety, &hellip; Continue reading &quot;STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-28T13:45:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjU5NCM3MjI2MjYxIzIwMTA1MTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements\",\"datePublished\":\"2025-10-28T13:45:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/\"},\"wordCount\":1194,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MjU5NCM3MjI2MjYxIzIwMTA1MTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/\",\"name\":\"STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MjU5NCM3MjI2MjYxIzIwMTA1MTQ=\",\"datePublished\":\"2025-10-28T13:45:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MjU5NCM3MjI2MjYxIzIwMTA1MTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MjU5NCM3MjI2MjYxIzIwMTA1MTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/","og_locale":"en_US","og_type":"article","og_title":"STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements - Market Newsdesk","og_description":"HORSHAM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) &#8212; STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies for the treatment of skin conditions such as acne, psoriasis, and vitiligo, today announced that its TheraClearX\u00ae acne treatment system has received regulatory clearance from the Mexican health authority, COFEPRIS (Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios), under Device Registration No. 3187E2024SSA, valid through November 2029. This certification represents a major milestone in STRATA\u2019s international expansion strategy, officially authorizing the importation, commercialization, and clinical use of TheraClearX\u00ae across Mexico\u2019s medical and aesthetic markets. Regulatory Clearance and Initial Launch The COFEPRIS medical device registration process, which typically spans 6 to 12 months, involves a detailed review of device safety, &hellip; Continue reading \"STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-28T13:45:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjU5NCM3MjI2MjYxIzIwMTA1MTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements","datePublished":"2025-10-28T13:45:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/"},"wordCount":1194,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjU5NCM3MjI2MjYxIzIwMTA1MTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/","name":"STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjU5NCM3MjI2MjYxIzIwMTA1MTQ=","datePublished":"2025-10-28T13:45:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjU5NCM3MjI2MjYxIzIwMTA1MTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjU5NCM3MjI2MjYxIzIwMTA1MTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strata-skin-sciences-announces-cofepris-clearance-of-theraclear-in-mexico-and-first-commercial-placements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear\u00ae in Mexico and First Commercial Placements"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/901099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=901099"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/901099\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=901099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=901099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=901099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}